Autolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at HC Wainwright

Posted by on May 14th, 2026

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) had its price objective hoisted by equities research analysts at HC Wainwright from $9.00 to $10.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other analysts also recently weighed in on AUTL. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Mizuho dropped their price target on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.75.

Read Our Latest Research Report on AUTL

Autolus Therapeutics Trading Down 7.3%

NASDAQ:AUTL traded down $0.13 during mid-day trading on Thursday, hitting $1.59. The stock had a trading volume of 2,561,326 shares, compared to its average volume of 1,743,251. The stock has a market capitalization of $421.84 million, a price-to-earnings ratio of -1.47 and a beta of 1.93. The company has a 50 day simple moving average of $1.49 and a 200-day simple moving average of $1.51. Autolus Therapeutics has a 52 week low of $1.18 and a 52 week high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $26.22 million for the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative net margin of 381.40% and a negative return on equity of 99.05%. As a group, equities research analysts anticipate that Autolus Therapeutics will post -1.04 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Mak Capital One LLC raised its holdings in shares of Autolus Therapeutics by 15.3% in the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after purchasing an additional 3,987,727 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Autolus Therapeutics by 12.2% in the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after purchasing an additional 1,900,000 shares in the last quarter. Schroder Investment Management Group raised its holdings in shares of Autolus Therapeutics by 12.5% in the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock worth $18,694,000 after purchasing an additional 1,056,092 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Autolus Therapeutics by 108.1% in the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock worth $3,308,000 after purchasing an additional 1,054,458 shares in the last quarter. Finally, Atle Fund Management AB raised its holdings in shares of Autolus Therapeutics by 5.8% in the 3rd quarter. Atle Fund Management AB now owns 1,169,634 shares of the company’s stock worth $1,907,000 after purchasing an additional 64,173 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

Featured Stories

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.